Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447758 | 0.93 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL10017853 | 0.89 | PARP1 (0.46) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13544696 | 0.87 | KDM4E (0.33) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11755814 | 0.86 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11755833 | 0.86 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL4447755 | 0.83 | PARP1 (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL4334172 | 0.83 | PARP1 (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL6885953 | 0.83 | — | — | |
| SCHEMBL6150675 | 0.81 | — | — | |
| SCHEMBL9176890 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | claimed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | claimed |
| EP-4452929-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | Immunic AG (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118576-A1 | DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE | IMMUNIC AG (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-115867268-A | Vidofladimor for the treatment or prevention of viral diseases | 埃慕尼克股份公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11376232-B2 | Vidofludimus for use in the treatment or prevention of viral diseases | IMMUNIC AG (DE) | 2022-07-05 | — | — | US | disclosed |
| WO-2021214033-A1 | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | IMMUNIC AG (DE) | 2021-10-28 | — | — | WO | disclosed |
| EP-3900717-A1 | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | Immunic AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210322351-A1 | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | IMMUNIC AG (DE) | 2021-10-21 | — | — | US | disclosed |
| US-20200215038-A1 | INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-07-09 | — | — | US | disclosed |
| US-20150328204-A1 | METHODS FOR TREATMENT OF MELANOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150306080-A1 | METHODS FOR TREATMENT OF MELANOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20140031383-A1 | METHODS FOR TREATMENT OF MELANOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2672963-A2 | METHODS FOR TREATMENT OF MELANOMA | Children's Medical Center Corporation (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109329-A2 | METHODS FOR TREATMENT OF MELANOMA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-08-16 | — | — | WO | disclosed |
| EP-2240487-B1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| CN-101111483-B | IGF-1R inhibitors | KYOWA HAKKO KIRIN CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| CN-101111483-A | IGF-1R inhibitors | KYOWA HAKKO KOGYO KK (JP) | 2008-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | ALDH1A1 162/4885KDM4E 2009/4885MAPT 110/4885 |
| US-20210322351-A1 | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | DHODH, ACE2, DPYD | ALDH1A1 192/4885KDM4E 3212/4885MAPT 752/4885 |
| US-11376232-B2 | Vidofludimus for use in the treatment or prevention of viral diseases | DHODH, ACE2, DPYD | ALDH1A1 192/4885KDM4E 3212/4885MAPT 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.